usamicro_0048|PHAS|0|total_current_assets|cash_on_hand|inventories_net|net_ppe|goodwill_and_intangible|liabilities|total_current_liabilities|total_long_term_liab|total_deposits|book_value_of_equity|retained_earnings|treasury_stock|ev_revenues|ev_earnings|ev_free_cash_flow|ev_assets|ps_ratio|pe_ratio|price_to_book_value|peg_ratio|debt_equity_ratio|dividend_yield|shareholder_yield_ttm|percent_of_shares_outstanding|receivables|payables|capital_stock|return_on_invested_capital|quality_ratio_fractile|momentum_fractile|market_beta_12_month|sustainable_growth_rate|institutional_investor_ownership_percentage|average_shares_outs_diluted|total_employee_number|eps|shares_outstanding|repurchase_of_capital_stock|ordinary_shares_number|payout_ratio|quick_ratio|normalized_eps|stock_buyback|effective_tax_rate|return_on_equity|net_income_ttm|revenues_ttm|dividend_per_share|revenues|gross_profit|sga_expense|pre_tax_income|net_income|interest_income|price|total_return_price|enterprise_value|average_volume_30|one_year_return|price_next_month|price_second_month
usamicro_0048|PHAS|1|PhaseBio Pharmaceuticals Inc Total Current Assets (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Cash and Short Term Investments (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Inventories (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Net PP&E (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Goodwill and Intangibles (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Liabilities (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Current Liabilities (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Long Term Liabilities (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Deposits (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Book Value (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Retained Earnings (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Treasury Stock (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc EV to Revenues|PhaseBio Pharmaceuticals Inc EV to Earnings|PhaseBio Pharmaceuticals Inc EV to Free Cash Flow|PhaseBio Pharmaceuticals Inc EV to Assets (Quarterly)|PhaseBio Pharmaceuticals Inc PS Ratio|PhaseBio Pharmaceuticals Inc PE Ratio|PhaseBio Pharmaceuticals Inc Price to Book Value|PhaseBio Pharmaceuticals Inc PEG Ratio|PhaseBio Pharmaceuticals Inc Debt to Equity Ratio|PhaseBio Pharmaceuticals Inc Dividend Yield|PhaseBio Pharmaceuticals Inc Shareholder Yield (TTM)|PhaseBio Pharmaceuticals Inc Percent of Shares Outstanding Short|PhaseBio Pharmaceuticals Inc Total Receivables (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Payables (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Total Capital Stock (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Return on Invested Capital|PhaseBio Pharmaceuticals Inc Quality Ratio Score|PhaseBio Pharmaceuticals Inc Momentum Score|PhaseBio Pharmaceuticals Inc Beta (1Y)|PhaseBio Pharmaceuticals Inc Sustainable Growth Rate (TTM)|PhaseBio Pharmaceuticals Inc Institutional Investor Ownership Percentage|PhaseBio Pharmaceuticals Inc Average Diluted Shares Outstanding (Quarterly)|PhaseBio Pharmaceuticals Inc Total Employees (Annual)|PhaseBio Pharmaceuticals Inc EPS Diluted (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Shares Outstanding|PhaseBio Pharmaceuticals Inc Repurchase of Capital Stock (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Ordinary Shares Number (Quarterly)|PhaseBio Pharmaceuticals Inc Payout Ratio|PhaseBio Pharmaceuticals Inc Quick Ratio (Quarterly)|PhaseBio Pharmaceuticals Inc Normalized Diluted EPS (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Stock Buybacks (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Effective Tax Rate (TTM)|PhaseBio Pharmaceuticals Inc Return on Equity|PhaseBio Pharmaceuticals Inc Net Income (TTM) (USD)|PhaseBio Pharmaceuticals Inc Revenue (TTM) (USD)|PhaseBio Pharmaceuticals Inc Dividend Per Share (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Revenue (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Gross Profit (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc SG&A Expense (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Pre-Tax Income (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Net Income (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Net Interest Income (Quarterly) (USD)|PhaseBio Pharmaceuticals Inc Price (USD)|PhaseBio Pharmaceuticals Inc Total Return Price (USD)|PhaseBio Pharmaceuticals Inc Enterprise Value (USD)|PhaseBio Pharmaceuticals Inc 30-Day Average Daily Volume|PhaseBio Pharmaceuticals Inc 1 Year Price Returns (Daily)||
usamicro_0048|PHAS|2|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_metric|percent_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|percent_USD_metric|figure_USD_metric|figure_USD_metric|figure_USD_beta|percent_USD_metric|percent_USD_metric|mil_figure_USD_metric|figure_whole_USD_metric|figure_money_USD_per_share_metric|mil_figure_USD_metric|mil_figure_money_USD_metric|mil_figure_USD_metric|percent_USD_metric|figure_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|percent_USD_metric|percent_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_per_share_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|mil_figure_money_USD_metric|figure_money_USD_price|figure_money_USD_price|mil_figure_money_USD_metric|figure_USD_metric|percent_USD_metric||
usamicro_0048|PHAS|4|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|daily|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|quarterly|quarterly|monthly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|daily|daily|daily|daily||
usamicro_0048|PHAS|5|101.333333333|101.333333333||101.333333333||101.333333333|101.333333333|101.333333333||101.333333333|101.333333333|101.333333333|1.44011976048|91.5|1.43913043478|91.1666666667|1.44011976048||1.43913043478||91.3333333333|1.45078740157|91.6666666667|15.2173913043|101.333333333|101.333333333|101.333333333|91.6666666667||30.5|30.4545454545|91.6666666667|30.5|91.2727272727|114|91.2727272727|35.3157894737||101.333333333|91.6666666667|91.3333333333|91.2727272727|91.375||91.6666666667|91.375|91.6666666667||91.3333333333||91.2727272727|91.2727272727|91.2727272727|91.2727272727|1.45078740157|1.45078740157|1.44509803922|1.4509394572|1.44747081712||
usamicro_0048|PHAS|6|9|9||9||9|9|9||9|9|9|334|4|460|6|334||460||6|508|3|46|9|9|9|3||10|11|3|14|11|8|11|19||9|3|6|11|8||3|8|3||6||11|11|11|11|508|508|510|479|257||
usamicro_0048|PHAS|7|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|daily|quarterly|daily|quarterly|daily|daily|daily|daily|quarterly|daily|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|monthly|monthly|quarterly|monthly|quarterly|yearly|quarterly|daily|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|quarterly|market_daily|market_daily|daily|market_daily|market_daily||
usamicro_0048|PHAS|201709||||||||||||||||||||||||||||||||||12.3923||-0.2066||||||-0.2017|||||||||0.565|-2.56|-2.56|-0.604|||||||
usamicro_0048|PHAS|201712|13.766|13.406||0.302||111.515|17.595|93.92||-97.416|-99.065|0.024||||||||||||||0.43|0.001|||||||12.3923|18|-0.2046|||19.5884|||-0.2861|||||||||0.628|-2.535|-2.535|-1.095|||||||
usamicro_0048|PHAS|201803||||||||||||||||||||||||||||||||||12.3923||-0.3553||||||-0.3426|||||||||0.643|-4.403|-4.403|-1.368|||||||
usamicro_0048|PHAS|201806|28.664|28.446||0.276||9.247|5.117|4.13||20.354|-110.142|0.024||||||||||||||0.569|0.015|||||||19.5884||-0.3407|||19.5884|||-0.2817||||-16.172|||||0.917|-6.674|-6.674|-1.411|||||||
usamicro_0048|PHAS|201809|24.968|24.341||0.251||143.662|7.688|135.974||-116.174|-118.043|0.024|||||||||-0.0646|||0.0171|0.411|1.576|0.001|||||||19.5884|19|-0.4034|23.8038||19.5884||3.2196|-0.2976||||-21.513|||0.411||1.056|-7.901|-7.901|-0.83|5.1|5.1|104.5584|69780.2667||2.85|
usamicro_0048|PHAS|201812|62.628|61.031||0.355||12.099|4.577|7.522||50.927|-122.911|0.024|||-1.291|0.3517|||1.4864||0.1473|||0.163|0.233|1.806|0.025|||||||24.4983|24|-0.26|24.4983||24.4983||13.3852|-0.371|-42.974|||-23.846|||0.257||2.241|-4.868|-4.868|0.072|3.09|3.09|22.1687|50348.0333||3.3|3.1589
usamicro_0048|PHAS|201903|54.075|51.894||2.279||12.304|3.797|8.507||44.082|-130.204|0.024|||-8.0674|3.3404|||8.506||0.1648|||0.5959|0.67|2.058|0.025|||||||24.4984|27|-0.3|24.4984||24.4984||13.8436|-0.3||||-26.736|||0.653||2.316|-7.293|-7.293|0.091|9.51|9.51|188.3498|343368.5333||13.1|10.68
usamicro_0048|PHAS|201906|94.897|90.342||2.509||15.829|5.746|10.083||81.609|-139.436|0.024|146.1781|-10.0998|-9.9287|3.0364|156.412||2.7464||0.1188||-23.8638|1.9965|1.18|3.047|0.029|-126.8111||||-181.2792|92.7001|27.9326|30|-0.33|28.6976||28.6976||15.928|-0.3292|-46.308||-181.2792|-29.294|2.024||0.703||2.404|-9.232|-9.232|0.272|13.12|13.12|295.8645|205671.3667||7.81|8.64
usamicro_0048|PHAS|201909|83.369|81.771||2.802||15.399|5.962|9.437||70.804|-150.827|0.024|25.8135|-1.4598|-1.3731|0.5552|59.4063||1.6934||0.1374||-74.7287|6.1067|0.583|1.659|0.029|-94.7865||4|1.3782|-124.8933|93.8506|28.7199|32|-0.4|28.7528||28.7528||13.8132|-0.4005|0.031||-124.8933|-32.784|1.854||0.241||2.803|-11.391|-11.391|0.185|4.17|4.17|47.8582|516493.3333|-19.4118|4.11|3.26
usamicro_0048|PHAS|201912|78.823|74.025||3.639||22.516|8.479|14.037||59.978|-162.158|0.024|49.3188|-2.9669|-2.8713|1.4115|71.1202||2.9305||0.2452||-27.149|7.9501|1.233|2.921|0.029|-55.077||7|2.1834|-63.837|91.407|28.7769|40|-0.39|28.7664||28.7664||8.8758|-0.3897|||-63.837|-39.247|2.361||0.764||3.663|-11.331|-11.331|-0.042|6.11|6.11|116.4417|576613.2|97.7346|4.98|4.21
usamicro_0048|PHAS|202003|72.541|59.441||4.285||23.372|7.495|15.877||53.486|-177.063|0.024|24.9343|-1.0791|-0.8994|0.6579|46.599||1.7811||0.2757||-50.0986|9.612|0.896|1.918|0.029|-63.9984||9|2.2926|-75.589|82.6816|28.7733|40|-0.52|28.7806||28.7806||8.0503|-0.5044|||-75.589|-46.859|2.028||0.32||3.159|-14.905|-14.905|-0.167|3.31|3.31|50.5668|304164.2|-65.1945|3.86|6.01
usamicro_0048|PHAS|202006|63.741|53.025||7.012||44.417|17.802|26.615||26.393|-205.205|0.024|46.6082|-2.0171|-1.7116|1.2298|65.2548||5.0302|||||10.8621||6.967|0.029|||3|1.9495||74.9851|28.8052|50|-0.98|28.8616||28.8616|||-0.852|-0.472|||-65.769|||||3.242|-28.142|-28.142|-0.358|4.6|4.6|94.5214|1221574.7333|-64.939|4|3.86
usamicro_0048|PHAS|202009|||||||||||||31.9288||-1.1725||49.7922||3.9023|||||13.0393||||||2|1.7528||73.0707||||||||||||||||||||||3.51|3.51|64.7516|247177.4333|-15.8273|3.095|